ID: ALA100955

Max Phase: Preclinical

Molecular Formula: C13H8BrNOS

Molecular Weight: 306.18

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C1Nc2ccccc2/C1=C\c1cc(Br)cs1

Standard InChI:  InChI=1S/C13H8BrNOS/c14-8-5-9(17-7-8)6-11-10-3-1-2-4-12(10)15-13(11)16/h1-7H,(H,15,16)/b11-6+

Standard InChI Key:  ONXUHKXDKGXHFK-IZZDOVSWSA-N

Associated Targets(non-human)

Vascular endothelial growth factor receptor 2 134 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 306.18Molecular Weight (Monoisotopic): 304.9510AlogP: 4.00#Rotatable Bonds: 1
Polar Surface Area: 29.10Molecular Species: NEUTRALHBA: 2HBD: 1
#RO5 Violations: 0HBA (Lipinski): 2HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.30CX Basic pKa: CX LogP: 3.95CX LogD: 3.95
Aromatic Rings: 2Heavy Atoms: 17QED Weighted: 0.79Np Likeness Score: -1.02

References

1. Vieth M, Cummins DJ..  (2000)  DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors.,  43  (16): [PMID:10956210] [10.1021/jm990609e]

Source